By Fineline Cube Anglikang Pharmaceuticals (SHE: 002940) announced that its partnership with Affinity for the IMD‑1005 project will be terminated. According to the termination notice sent by Affinity, and based on comprehensive considerations regarding its overall strategic layout and pipeline prioritization, the decision was made to independently advance the R&D, manufacturing, and commercialization of IMD‑1005 in the agreed territories at this stage, rather than collaborating with third parties via out‑licensing.
Transaction Milestone
| Field | Detail |
|---|---|
| Company | Anglikang Pharmaceuticals (SHE: 002940) |
| Partner | Affinity |
| Asset | IMD‑1005 — tumor microenvironment‑activated anti‑CD47 antibody |
| Action | Partnership termination; IMD‑1005 project collaboration ends |
| Notice Source | Termination notice sent by Affinity |
| Stated Rationale | Overall strategic layout and pipeline prioritization; independent advancement preferred over third‑party out‑licensing at this stage |
| Date | 07 Sep 2026 |
| Territory Implication | Affinity to independently advance R&D, manufacturing, and commercialization in the agreed territories |
Drug Profile & Mechanism of Action
- Molecule: IMD‑1005, developed by Affinity.
- Target: CD47, a key “don’t eat me” signal exploited by tumors to evade innate immune clearance.
- Innovation: A globally novel tumor microenvironment‑activated antibody design, intended to selectively engage within the tumor milieu.
- Differentiation: The tumor microenvironment‑activation concept distinguishes IMD‑1005 from conventional anti‑CD47 approaches in the immuno‑oncology landscape.
Licensing Agreement Background
| Term | Detail |
|---|---|
| Agreement Date | August 2025 |
| Parties | Anglikang Pharmaceuticals and Affinity |
| Structure | Exclusive in‑licensing agreement |
| Rights Acquired | Development, manufacturing, and commercialization rights |
| Territories | Mainland China, Hong Kong, Macao, and Taiwan |
| Total Commitment | Up to RMB 770 million |
Under the August 2025 licensing agreement, Anglikang Pharmaceuticals committed up to RMB 770 million to acquire the exclusive rights to develop, manufacture, and commercialize IMD‑1005 in Mainland China, Hong Kong, Macao, and Taiwan. The September 2026 termination notice from Affinity ends that collaboration, with Affinity opting to advance the CD47 program independently in the agreed territories rather than continue via out‑licensing to third parties at this stage.
Market Impact & Outlook
- Strategic Reprioritization: The termination reflects Affinity‘s comprehensive review of its strategic layout and pipeline prioritization, favoring independent control of the IMD‑1005 program.
- Portfolio Effect for Anglikang: Anglikang Pharmaceuticals will no longer pursue IMD‑1005 under the 2025 in‑licensing framework; the company did not quantify financial implications in the announcement.
- Asset Trajectory: The globally novel tumor microenvironment‑activated anti‑CD47 antibody remains an active development asset, now advanced solely by Affinity in the agreed territories.
- Sector Context: The move underscores continuing realignment in immuno‑oncology partnerships, where sponsors increasingly weigh internal advancement against out‑licensing as pipeline strategies evolve.
Forward‑Looking Statements — This brief contains forward‑looking statements regarding the termination of the partnership between Anglikang Pharmaceuticals and Affinity and the future development of IMD‑1005, including Affinity‘s independent advancement of the tumor microenvironment‑activated CD47 antibody. Such statements are based on current expectations and are subject to risks and uncertainties, including R&D, regulatory review, and commercialization risks. Actual results may differ materially. Nothing herein constitutes investment advice or an offer to buy or sell any securities.-Fineline Info & Tech